يعرض 1 - 20 نتائج من 51 نتيجة بحث عن '"E. A. Bryun"', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
  7. 7
    Academic Journal

    المساهمون: Исследование выполнено при финансовой поддержке Российского фонда фундаментальных исследований в рамках научного проекта №18-315-00005.

    المصدر: Pharmacogenetics and Pharmacogenomics; № 2 (2018); 4-11 ; Фармакогенетика и фармакогеномика; № 2 (2018); 4-11 ; 2588-0527 ; 2686-8849

    وصف الملف: application/pdf

    Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/81/81; Haefely W.E. Pharmacology of the Benzodiazepine Receptor. Eur Arch Psychiatry Neurol Sci 1989, 238(5–6):294–301.; Mckernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R. et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000, 3(6):587–592.; Low K., Crestani F., Keist R., Benke D.,Brunig I., Benson J.A. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000, 290(5489):131–134.; Keist R., Mandelli M., Ohler H.M, Rudolph U.W.E. Molecular Targets for the Myorelaxant Action of Diazepam. Mol Pharmacol 2001, 59(3) 442–445.; Amato L., Minozzi S., Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev 2011, 15;(6).; Sachdeva A., Choudhary M., Chandra M. Alcohol withdrawal syndrome: Benzodiazepines and beyond. J Clin Diagnostic Res 2015. 9(9):VE01-VE07.; Афанасьев В.В., подред. Алкогольный абстинентный синдром. СПб: «Интермедика», 2002. с. 336.; Ладыженский М.Я., Городничев А.В., Костюкова Е.Г. Бензодиазепиновые анксиолитики: востребованы ли они сегодня? Современная терапия психических расстройств 2014, 2: 20–25.; Осадший Ю.Ю., Вобленко Р.А., Арчаков Д.С., Тараканова Е.А. Место бензодиазепинов в современной терапии психических расстройств (обзор доказательных исследований). Современнаятерапияпсихическихрасстройств 2016, 1:2–10.; Lu X.M., Zhu J.P., Zhou X.M. The effect of benzodiazepines on insomnia in patients with chronic obstructive pulmonary disease: a metaanalysis of treatment efficacy and safety. Int J Chron Obstruct Pulmon Dis 2016, 11:675–685.; Maskell P.D., De Paoli G., Seetohul L., Pounder D.J. Phenazepam: The drug that came in from the cold. J Forensic Leg Med 2012, 19(3):122–125.; Ivashchenko D.V., Rudik A.V., Poloznikov A.A., Nikulin S.V., Smirnov V.V., Tonevitsky A.G. et al. Which cytochrome P-450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018, 33(2):65–73.; Lamba J., Hebert J.M., Schuetz E.G., Klein T.E., Altman R.B. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 2012, 22(7):555–558.; Fukasawa T., Suzuki A., Otani K. Effects of genetic polymorphism of cytochrome P-450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007, 32(4):333–341.; Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat genet 2001, 27(4):383–391.; Werk A.N., Cascorbi I. Functional gene variants of CYP3A4. Clin pharmacol ther 2014, 96(3):340–348.; Zanger U.M., Schwab M. Cytochrome P-450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013, 1(138):103–141.; Miao J., Jin Y., Marunde R.L., Kim S., Quinney S., Radovich M. et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J 2009, 9(5):319–326.; He P., Court M., Greenblatt D., Vonmotke L. Genotype-phenotype associations of cytochrome P-450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 2005, 77(5):373–387.; de Jonge H., Elens L., de Loor H., van Schaik R.H., Kuypers D.R.J. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics J 2015, 15(2):144–152.; Floyd M.D., Gervasini G., Masica A.L., Mayo G., George A.L., Bhat K. et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in Europeanand African-American men and women. Pharmacogenetics 2003, 13(10):595–606.; Иващенко Д.В., Рыжикова К.А., Созаева Ж.А., Застрожин М.С., Гришина Е.А., Агузаров А.Д. исоавт. Изучение ассоциации полиморфизма гена CYP3A5 rs776746 с безопасностью феназепама у пациентов с синдромом отмены алкоголя. Наркология 2017, 3(181): 36–47.; Elens L., van Gelder T., Hesselink D.A., Haufroid V., van Schaik R. CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013, 14(1):47–62.; Wang D., Guo Y., Wrighton S.A., Cooke G.E., Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011, 11(4):274–286.; Okubo M., Murayama N., Shimizu M., Shimada T., Guengerich F.P., Yamazaki H. The CYP3A4 intron 6 >T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 2013, 38 (3):349–354.; https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/81

  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20